Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 17;218(11):e20210911. doi: 10.1084/jem.20210911

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Hermann et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 1. — PC-afflicted males show decreased survival and increased metastasis specifically in the liver. (A) Relative 1-, 3-, and 5-yr survival rates of female (n = 101,357) and male (n = 101,227) PC patients. Data were derived from the ECIS database. A paired samples t test was employed for statistics. (B) Survival of female (n = 22) and male (n = 34) PDAC-bearing KPC mice. The log-rank test was employed for statistics. (C–F) The proportion of female (n = 18) and male (n = 23) patients with metastatic PC (M1, UICC stage IV) with (yes) or without (no) metastases in the liver (C), LN (D), lung (E), or peritoneum (F). The χ² test was employed for statistics. (G–K) Disease recurrence in the pancreas (G), LN (H), lung (I), peritoneum (J), or liver (K) of female (n = 106) or male (n = 112) PDAC patients diagnosed without synchronous metastases (M0) and treated with primary tumor resection. The log-rank test was employed for statistics. *, P ≤ 0.05 (A–K).